Long-term survival and cure fraction in patients with advanced hepatocellular carcinoma under immunotherapy in randomized controlled trials and real-world data

Lung, Respiratory and Thoracic Cancer

Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis

Lancet Oncol

Di Federico A, Stumpo S, Mantuano F, De Giglio A, Lo Bianco F, Pecci F, Alessi JV, Wang X, Sperandi F, Melotti B, Gelsomino F, Skoulidis F, Garassino MC, Peters S, Awad MM, Ardizzoni A, Ricciuti B

doi: 10.1016/S1470-2045(25)00429-2

Genitourinary Cancer

Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Outcomes from the JAVELIN Bladder 100 Trial in Patients with Nonvisceral or Lymph Node-only Disease

Eur Urol

Bellmunt J, Powles T, Park SH, Voog E, Valderrama BP, Gurney H, Ullén A, Loriot Y, Sridhar SS, Tsuchiya N, Sternberg CN, Aragon-Ching JB, Petrylak DP, Climent Duran MA, Tyroller K, Hoffman J, Jacob N, Grivas P, Gupta S

doi: 10.1016/j.eururo.2025.05.017

Breast Cancer

Real-world progression-free survival and overall survival in patients with HR(+)/HER2(-) advanced breast cancer treated in first-line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study

Int J Cancer

Fasching PA, Brucker C, Decker T, Engel A, Göhler T, Jackisch C, Janssen J, Köhler A, Lüdtke-Heckenkamp K, Lüftner D, Marmé F, van Mackelenbergh M, Rautenberg B, Schmidt M, Weide R, Wimberger P, Kisseleff E, Pfister C, Quiering C, Roos C, Wöckel A

doi: 10.1002/ijc.70397

Gastrointestinal Cancer

Determinants of long-term survival from atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma

Eur J Cancer

Lee PC, Cortellini A, Stefanini B, Yoo C, Chon HJ, Cheon J, Kudo M, Nishida N, Scheiner B, Pinter M, Lombardi P, Fulgenzi CAM, D'Alessio A, Brunetti L, Torkpour A, Valenzi E, Crowley F, Marron TU, Hsu WF, Celsa C, Cabibbo G, Cammà C, Galle PR, Vivaldi C, Masi G, Sharma R, Lin RP, Lin CY, Wietharn B, Saeed A, Tovoli F, Piscaglia F, Dalbeni A, Auriemma A, Sacerdoti D, Parisi A, Manfredi GF, Dondo A, Rimassa L, Pirisi M, Schönlein M, von Felden J, Singal AG, Parkih ND, Andanamala H, Ulahannan S, Roehlen N, Thimme R, Huang YH, Pinato DJ

doi: 10.1016/j.ejca.2026.116749

Genitourinary Cancer

Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial

Ann Oncol

Tripathi A, Chen Y, Jarrard DF, Garcia JA, Dreicer R, Liu G, Hussain MH, Shevrin DH, Cooney MM, Eisenberger MA, Kohli M, Plimack ER, Vogelzang NJ, Picus J, Carducci MA, DiPaola RS, Sweeney CJ

doi: 10.1016/j.annonc.2025.08.004

Gastrointestinal Cancer

Twenty year survival of advanced gastrointestinal stromal tumours treated with imatinib Exploratory long-term follow-up of the BFR14 trial

Ann Oncol

Blay JY, Devin Q, Toulmonde M, Dufresne A, Penel N, Adenis A, Rios M, Bertucci F, Duffaud F, Firmin N, Valentin T, Bompas E, Collard O, Pracht M, Hervieu A, Verret B, Ray-Coquard I, Cassier P, Henon C, Perol D, Italiano A, Chabaud S, Le Cesne A

doi: 10.1016/j.annonc.2025.05.535

Central Nervous System Tumors

Long-term survival and cure fraction estimates for paediatric central nervous system tumours in 31 European countries (EUROCARE-6): a population-based study

Lancet Oncol

Hoogendijk R, Capocaccia R, van der Lugt J, Kranendonk MEG, Hoving EW, Wesseling P, Visser O, van Vuurden DG, Gatta G, Karim-Kos HE, EUROCARE working group

doi: 10.1016/S1470-2045(25)00297-9

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Real-world outcomes versus clinical trial results of first-line immunotherapy with or without chemotherapy in patients with metastatic non-small-cell lung cancer: the CORRELATE study

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

ESMO Open

Peters S, Salomonsen RJ, Diaz Perez I, Shcherbakova T, Wang A, Cai L, Sadow S, Liu SV

doi: 10.1016/j.esmoop.2025.106031

Genitourinary Cancer

Long-term Results from the LEA Randomized Trial: Extended Versus Standard Lymph Node Dissection in Patients with Bladder Cancer Undergoing Radical Cystectomy

Eur Urol

Heck MM, Lehmann J, Amiel T, Rübben H, Albers P, Wolff JM, Frohneberg D, de Geeter P, Heidenreich A, Kälble T, Stöckle M, Schnöller T, Stenzl A, Müller M, Truss M, Roth S, Liehr UB, Leißner J, Bregenzer T, Rexer H, Retz M, Gschwend JE

doi: 10.1016/j.eururo.2025.09.001

Related content

Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis

Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Outcomes from the JAVELIN Bladder 100 Trial in Patients with Nonvisceral or Lymph Node-only Disease

Real-world progression-free survival and overall survival in patients with HR(+)/HER2(-) advanced breast cancer treated in first-line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study

Determinants of long-term survival from atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma

Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial

Twenty year survival of advanced gastrointestinal stromal tumours treated with imatinib Exploratory long-term follow-up of the BFR14 trial

Long-term survival and cure fraction estimates for paediatric central nervous system tumours in 31 European countries (EUROCARE-6): a population-based study

Real-world outcomes versus clinical trial results of first-line immunotherapy with or without chemotherapy in patients with metastatic non-small-cell lung cancer: the CORRELATE study

Long-term Results from the LEA Randomized Trial: Extended Versus Standard Lymph Node Dissection in Patients with Bladder Cancer Undergoing Radical Cystectomy